Stockscreener 앱 받기
5.325
2.74%
-0.15
시간 외 거래:
3.75
-1.575
-29.58%
전일 마감가:
$5.475
열려 있는:
$5.4
하루 거래량:
1.97M
Relative Volume:
3.32
시가총액:
$317.95M
수익:
-
순이익/손실:
$-44.80M
주가수익비율:
-7.10
EPS:
-0.75
순현금흐름:
$-30.67M
1주 성능:
-15.48%
1개월 성능:
+4.21%
6개월 성능:
+0.47%
1년 성능:
+50.00%
1일 변동 폭
$5.22
$5.8799
1주일 범위
$5.04
$6.73
52주 변동 폭
$3.10
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.325 | 317.95M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Does Candel Therapeutics Inc (NASDAQ: CADL) Still Need To Convince Analysts? - Stocks Register
Does QXO Inc (NYSE: QXO) Still Look Hot This Week? - Stocks Register
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Raymond James Financial Inc. Invests $3.63 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Trend Tracker for (ALDX) - news.stocktradersdaily.com
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Above 50-Day Moving Average – Here’s Why - Defense World
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDX - Business Wire
BTIG maintains Aldeyra stock Buy rating, $11 target By Investing.com - Investing.com Canada
Aldeyra Therapeutics Beats Investor Suit Over Eye Drug Misses - Bloomberg Law News
(ALDX) On The My Stocks Page - Stock Traders Daily
Biotech Wins Dismissal Of Investor Fraud Claims - Law360
ALDX stock touches 52-week high at $6.93 amid robust gains - Investing.com Australia
ALDX stock touches 52-week high at $6.93 amid robust gains By Investing.com - Investing.com South Africa
Tech Stocks Defying Market Volatility: Meet the Pioneers of Tomorrow’s Economy - DSA
High Growth Tech Stocks To Watch In The US March 2025 - Simply Wall St
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference - Business Wire
Aldeyra Therapeutics CEO Scheduled for Fireside Chat at Major Healthcare Conference - Stock Titan
Aldeyra Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Q1 Earnings Estimate for ALDX Issued By HC Wainwright - Defense World
How to Take Advantage of moves in (ALDX) - Stock Traders Daily
Aldeyra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aldeyra Therapeutics Is Severely Undervalued Before PDUFA - Seeking Alpha
Chronic Cough Market Expected to rise, 2034 | Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., expected to drive market - Barchart
Chronic Cough Market Expected to rise, 2034 | Merck & Co, Kyorin - openPR
Aldeyra Therapeutics (NASDAQ:ALDX) Receives Buy Rating from HC Wainwright - Defense World
Aldeyra Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Aldeyra Therapeutics Inc [ALDX] Insider Activity: An Update for Investors - Knox Daily
Clearside Biomedical Inc. Revolutionizes Panuveitis Treatment With Innovative Xipere Product: Key Trend in ... - WhaTech
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Aldeyra Therapeutics, Inc. SEC 10-K Report - TradingView
Best Stocks Under $10 • Charts Updated Daily - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Aldeyra Therapeutics, Inc. (ALDX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Thursday - Defense World
(ALDX) Trading Report - Stock Traders Daily
AlphaCentric Advisors LLC Acquires New Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
In-Depth Analysis Of The Chronic Plaque Psoriasis Market: Key Drivers, Trends, Growth Opportunities And - EIN News
Global Microtome Market to Exhibit Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire
Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA - openPR
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge - GlobeNewswire
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge Bankshares, and Amplitude Investigation ... - The Bakersfield Californian
ALDX stock touches 52-week high at $6.6 amid robust annual gains - MSN
Why Aldeyra Therapeutics Inc (NASDAQ: ALDX) Is A Great Stock Pick For Momentum Investors - Stocks Register
Dry Eye Disease Clinical Trial Pipeline | 45+ Companies Pioneering the Future of Treatment - EIN News
(ALDX) Proactive Strategies - Stock Traders Daily
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stake Raised by SG Americas Securities LLC - Defense World
Dry Eye Disease Market Poised for Major Advancements by 2034, Reveals DelveInsight - WICZ
Aldeyra Therapeutics Inc (ALDX) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Retinitis Pigmentosa Treatment Market Industry Growth - openPR
Exclusive Fireside Chat: Aldeyra CEO Reveals Company Strategy at Major Healthcare Conference - StockTitan
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):